- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05438836
Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer (ROAR-A)
September 21, 2023 updated by: Eva Serup-Hansen, Herlev Hospital
ROAR-A: Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer
A single-arm, prospective, Phase II, single-center clinical trial that will investigate if daily online adaptive radiotherapy for anal cancer will significantly reduce early treatment-related GI toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
205
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Eva Serup-Hansen, MD, PhD
- Phone Number: +4538689084
- Email: eva.serup-hansen@regionh.dk
Study Contact Backup
- Name: katrine s Storm, MD
- Phone Number: +4538686269
- Email: katrine.smedegaard.storm@regionh.dk
Study Locations
-
-
-
Herlev, Denmark, 2730
- Recruiting
- Oncology dept, Herlev and Gentofte Hospital
-
Contact:
- katrine s Storm, MD
- Phone Number: +4538686269
- Email: katrine.smedegaard.storm@regionh.dk
-
Contact:
- Eva S Serup-Hansen, MD, PhD
- Phone Number: +4538689084
- Email: eva.serup-hansen@regionh.dk
-
Principal Investigator:
- Eva Serup-Hansen, MD, PhD
-
Sub-Investigator:
- katrine S Storm, MD
-
Sub-Investigator:
- Anna-Lene Fromm, MD
-
Sub-Investigator:
- Laura V Diness, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Patients with non-metastatic squamous cell carcinoma of the anus, referred for chemo-radiotherapy with curative intent.
Description
Inclusion Criteria:
- Biopsy-verified anal cancer
- Eligible for curative intended radiotherapy
- Written and oral consent
Exclusion Criteria:
- Other malignant disease within the past 5 years (excluding basal cell carcinoma)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Online adaptive radiotherapy
Daily online adaptive radiotherapy
|
Online adaptive radiotherapy compared to standard non-adaptive Image-Guided Radiotherapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Early Rate of Common Terminology Criteria for Adverse Events (CTCAE) Gastrointestinal Toxicity grade 2 or more (scale from 0-5, 5 being the highest)
Time Frame: from mid-treatment to 3 months after end of treatment
|
percentage of patients with grade 2 or more early treatment-related Gastrointestinal-toxicity
|
from mid-treatment to 3 months after end of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All Early Common Terminology Criteria for Adverse Events (CTCAE) Treatment Related Toxicities. Grade 1-5 (5 being the highest)
Time Frame: from mid-treatment to 3 months after end of treatment
|
percentage of patients with grade 2 or more early treatment-related toxicity
|
from mid-treatment to 3 months after end of treatment
|
All Late Common Terminology Criteria for Adverse Events (CTCAE) Treatment Related Toxicities
Time Frame: From 3 months after end of treatment to 5 years follow-up
|
percentage of patients with grade 2 or more late treatment-related toxicity
|
From 3 months after end of treatment to 5 years follow-up
|
Patient Reported Outcomes (PRO)
Time Frame: from baseline to 5 years follow-up
|
Collection of National Cancer Institute Patient Reported Outcome-Common Terminology Criteria for Adverse Events (NCI PRO-CTCAE) questionnaire (scale from none to a lot) and comparison to Common Terminology Criteria for Adverse Events (CTCAE) and dosimetry data
|
from baseline to 5 years follow-up
|
European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Assessment
Time Frame: from baseline to 5 years follow-up
|
Collection ofEuropean Organisation for Research and Treatment of Cancer (EORTC) Quality of life questionnaire C30
|
from baseline to 5 years follow-up
|
Progression Free Survival
Time Frame: From time of inclusion to disease progression, assessed up to 5 years follow-up
|
Progression free survival (from time of inclusion to disease progression)
|
From time of inclusion to disease progression, assessed up to 5 years follow-up
|
Overall Survival
Time Frame: From time of inclusion to death from any cause, assessed up to 5 years follow-up
|
Overall survival
|
From time of inclusion to death from any cause, assessed up to 5 years follow-up
|
Disease Free Survival
Time Frame: From time of inclusion to death from bladder cancer, assessed up to 5 years follow-up
|
Disease Free Survival
|
From time of inclusion to death from bladder cancer, assessed up to 5 years follow-up
|
Treatment Related Hospitalization
Time Frame: From of start of radiation therapy through 5 year follow-up
|
Hospitalization due to radiation therapy treatment related toxicity
|
From of start of radiation therapy through 5 year follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Eva S Serup-Hansen, MD, PhD, Herlev Og Gentofte Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2022
Primary Completion (Estimated)
January 1, 2026
Study Completion (Estimated)
January 1, 2031
Study Registration Dates
First Submitted
June 27, 2022
First Submitted That Met QC Criteria
June 27, 2022
First Posted (Actual)
June 30, 2022
Study Record Updates
Last Update Posted (Actual)
September 25, 2023
Last Update Submitted That Met QC Criteria
September 21, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Rectal Neoplasms
- Anus Diseases
- Carcinoma
- Anus Neoplasms
Other Study ID Numbers
- H-21028093
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anal Squamous Cell Carcinoma
-
National Cancer Institute (NCI)Active, not recruitingAnal Canal Squamous Cell Carcinoma | Metastatic Anal Canal Carcinoma | Stage IV Anal Canal Cancer AJCC v6 and v7United States, Canada
-
National Cancer Institute (NCI)RecruitingAnal Canal Cloacogenic Carcinoma | Metastatic Anal Squamous Cell Carcinoma | Recurrent Anal Squamous Cell Carcinoma | Stage III Anal Cancer AJCC v8 | Stage IV Anal Cancer AJCC v8 | Unresectable Anal Squamous Cell Carcinoma | Anal Basaloid Squamous Cell CarcinomaUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RecruitingAnal Basaloid Carcinoma | Anal Canal Cloacogenic Carcinoma | Anal Canal Squamous Cell Carcinoma | Anal Margin Squamous Cell Carcinoma | Stage I Anal Cancer AJCC v8 | Stage IIA Anal Cancer AJCC v8United States
-
National Cancer Institute (NCI)Canadian Cancer Trials GroupActive, not recruitingAnal Canal Cloacogenic Carcinoma | Stage III Anal Cancer AJCC v8 | Anal Margin Squamous Cell Carcinoma | Stage IIB Anal Cancer AJCC v8 | Anal Basaloid Squamous Cell CarcinomaUnited States, Canada
-
National Cancer Institute (NCI)RecruitingHIV Infection | Anal Squamous Cell Carcinoma | Anal Canal Cloacogenic Carcinoma | Stage III Anal Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Anal Margin Squamous Cell Carcinoma | AIDS-Related Anal Carcinoma | Rectal Squamous Cell Carcinoma | Stage I Anal Cancer AJCC... and other conditionsUnited States
-
Incyte CorporationCompletedSquamous Cell Carcinoma of Anal CanalSpain, United Kingdom, United States, Germany, Belgium, France, Denmark, Italy, Norway
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruitingAnal Canal Cancer | Anal Squamous Cell Carcinoma | Anal Cancer | Anal Canal Cancer Stage IIIChina
-
Centre Hospitalier Universitaire VaudoisTerminated
-
Instituto do Cancer do Estado de São PauloCompleted
-
Sun Yat-sen UniversityEnrolling by invitationAnal Canal Cancer | Anal Squamous Cell Carcinoma | Anal Cancer | Anal Canal Cancer Stage I | Anal Canal Cancer Stage II | Anal Canal Cancer Stage IIIChina
Clinical Trials on online adaptive radiotherapy
-
Amsterdam UMC, location VUmcRecruiting
-
Peking Union Medical College HospitalActive, not recruitingUterine Cervical NeoplasmChina
-
Peking Union Medical College HospitalActive, not recruitingEndometrial Neoplasms | Uterine Cervical NeoplasmChina
-
Peking Union Medical College HospitalActive, not recruitingEndometrial Neoplasms | Uterine Cervical NeoplasmChina
-
University of AarhusOdense University Hospital; Copenhagen University Hospital at HerlevCompletedAdverse Effects for Adaptive RT of Bladder CancerDenmark
-
University Hospital, EssenRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Adaptive Radiotherapy | OptimizationGermany
-
Haukeland University HospitalRecruiting
-
M.D. Anderson Cancer CenterRecruiting
-
The University of Hong Kong-Shenzhen HospitalUnknownCervical Cancer | Artificial Intelligence | Radiotherapy Side Effect | BiomarkerChina